<DOC>
	<DOC>NCT01928394</DOC>
	<brief_summary>ADDENDUM- PLEASE NOTE: AS OF JANUARY 2017, THIS STUDY IS ONLY RECRUITING PATEINTS WITH BLADDER AND PANCREATIC CANCER. To investigate the safety and efficacy of Nivolumab as a single agent or in combination with Ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of Nivolumab with Ipilimumab and Cobimetinib is also investigated in PC.</brief_summary>
	<brief_title>A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description>The following Tumor Types are now closed for enrollment: Triple Negative Breast Cancer Gastric Cancer Ovarian Cancer Small Cell Lung Cancer</detailed_description>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with histologically confirmed locally advanced or metastatic disease of the following tumor types: Triple Negative Breast Cancer Gastric Cancer Pancreatic Cancer Small Cell Lung Cancer Bladder Cancer Ovarian Cancer Subjects must have measurable disease Eastern Cooperative Oncology Group (ECOG) of 0 or 1 Adequate hematological and organ function as confirmed by laboratory values Active brain metastases or leptomeningeal metastases Subjects with active, known or suspected autoimmune disease Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment Prior therapy with experimental antitumor vaccines; any T cell costimulation or checkpoint pathways, such as antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>